H elicobacter pylori is an important human pathogen thought to play a causative role in many gastrointestinal diseases including gastritis, peptic ulcer, and gastric cancer. The efficacy of the commonly recommended empiric combination therapies used in eradicating H pylori has declined to the point that in most regions traditional empiric therapies are no longer effective. 1 Although there have been a number of recently published guidelines and recommendations for treating H pylori, 2-5 failures still are common. 6 Resistance to clarithromycin, metronidazole, and fluoroquinolones increasingly are reported and are associated strongly with treatment failures. Cultureguided treatment is standard for infectious diseases in which antimicrobial resistance is common because it allows therapy to be tailored to antimicrobial susceptibilities. 7 Susceptibility-based therapy is especially important to guide tailored treatment after failure of standard empiric therapies. However, the effectiveness of cultureguided and sensitivity-based treatment of H pylori in a referral setting in the United States is unknown.
Methods
This was a retrospective cohort study of patients referred after failure to eradicate H pylori during 2011 to 2016 at the Baylor Clinic in Houston, Texas. We evaluated all patients with an esophagogastroduodenoscopy with gastric biopsy specimens for histology and culture with susceptibility testing. One to 2 biopsy specimens were transported in saline containing tubes on ice to the H pylori culture laboratory at the Michael E. DeBakey VA Medical Center. H pylori infection was diagnosed by histology and confirmed by immunohistochemical staining. H pylori was identified by culture when the oxidase, catalase, and urease reactions were positive. Susceptibility to clarithromycin, metronidazole, amoxicillin, and levofloxacin was assessed by using the E-test (AB Biodisk, Solna, Sweden) for all samples, and susceptibility to tetracycline was assessed for a subset of samples. H pylori eradication was evaluated by the urea breath test or the fecal antigen test while off of proton pump inhibitors for a minimum of 2 weeks. We evaluated patients and their outcomes as of May 20, 2017.
Results
We evaluated 49 referred patients who on average had 3.3 previous H pylori treatments (range, 1-12 treatments). Their mean age was 51 years, 41 (84%) were women, and their racial groups were as follows: 41% were white, 31% were Hispanic or Latino, 10% were black or African American, 6% were Asian, 6% were South Asian, and 6% declined to answer. No allergies to the antibiotics used in the treatment for H pylori were reported in 30 patients (61%); 8 patients (16%) reported an allergy to penicillin, 2 patients (4%) reported an allergy to clarithromycin, 1 patient (2%) reported an allergy to metronidazole, 1 patient (2%) reported an allergy to tetracycline, and 7 patients (15%) reported an allergy to a combination of these antibiotics. The culture positivity of these 49 patients was only 82% (40 patients). Of these, 93% (n ¼ 37) were resistant to metronidazole, 88% (n ¼ 35) were resistant to clarithromycin, and 73% (n ¼ 29) were resistant to levofloxacin. No strain was resistant to amoxicillin. Tetracycline sensitivity was tested in 19 samples and only 1 strain (5%) obtained from a subject from the United States was resistant.
After culture and allergy-guided treatment, 24 patients (60%) were confirmed to achieve H pylori eradication. Of the 24 participants, 17 (71%) received 1 course of treatment, 4 (17%) received 2 treatments, anddrug allergy, which limits use of 1 or more antimicrobials. Clearly, the approach used here provided some cures (42.5% with the first regimen used), but overall the results were not very satisfactory. Lessons learned included the need to better coordinate with the culture laboratory to ensure availability of special transport media or the ability to freeze the sample in transport media until transport to the off-site laboratory. Ideally, culture should be available on site. Although it is challenging to separate a difficult infection (multiple resistances) from the poorly adherent patient, it is difficult to achieve reliably high cure rates even in the presence of susceptibility testing. We suggest that the result of all H pylori treatments are logged to provide feedback so that failure of therapy is identified early. After treatment failures, patients probably should be managed either by experts in the field or within a system that provides reliable feedback so that problems can be identified and corrected or the poorly performing regimen can be abandoned. Figure 1 . The distribution of the number of culture-guided H pylori treatments required to achieve a cure in 24 patients with multiple previous failed empiric treatments.
